PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27149910-0	2016	Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.	Diltiazem	95-104	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	37-43	
32803289-8	2021	CONCLUSION: Moderate effect of diltiazem on tacrolimus sparing, which might relate to the polymorphisms of CYP3A4, CYP3A5, ABCB1, and SLCO1B3, was documented.	Diltiazem	31-40	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	115-121	
27149910-10	2016	WHAT IS NEW AND CONCLUSION: The CYP3A4*1G and CYP3A5*3 genetic polymorphisms are closely related to the trough concentration/dose ratios and pharmacokinetics of diltiazem and its main metabolites in Chinese adult renal transplant patients.	Diltiazem	161-170	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	46-52	
30471066-10	2019	In contrast, among CYP3A5 expressors receiving diltiazem, AUCss, 0-24 did not change significantly upon conversion [229 (170-296) vs. 221 (123-342) ng h/mL, p = 0.575, n = 10].	Diltiazem	47-56	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	19-25	
27149910-3	2016	This study was carried out to investigate the impacts of the CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the trough concentration/dose ratios and pharmacokinetics of diltiazem and its main metabolites in Chinese adult renal transplant patients.	Diltiazem	170-179	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	75-81	
27149910-7	2016	RESULTS AND DISCUSSION: The dose-adjusted concentrations and pharmacokinetics of diltiazem and its main metabolites were significantly affected by CYP3A4 *1G and CYP3A5*3 alleles.	Diltiazem	81-90	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	162-168	
27149910-9	2016	The dose-adjusted trough levels and AUC of diltiazem and its main metabolites were significantly lower in CYP3A5*1*1 carriers than in CYP3A5*3 carriers (P < 0 05).	Diltiazem	43-52	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	106-112	
27149910-9	2016	The dose-adjusted trough levels and AUC of diltiazem and its main metabolites were significantly lower in CYP3A5*1*1 carriers than in CYP3A5*3 carriers (P < 0 05).	Diltiazem	43-52	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	134-140	
23432535-9	2013	Results showed that CYP3A5 expressers needed more tacrolimus to reach therapeutic concentration window and were more susceptible to diltiazem-induced concentration increase than CYP3A5 non-expressers.	Diltiazem	132-141	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	20-26	
23700791-0	2013	Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.	Diltiazem	77-86	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	11-17	
23700791-1	2013	PURPOSE: To assess the possibility of using CYP2D6 10 +/- CYP3A5*3 as biomarkers to predict the pharmacokinetics of diltiazem and its two metabolites among healthy Chinese subjects.	Diltiazem	116-125	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	58-64	
15377640-1	2004	The objectives of this study were to characterize and compare the reversible inhibition and time-dependent inactivation of cytochromes P450 3A4 and 3A5 (CYP3A4 and CYP3A5) by erythromycin, diltiazem, and nicardipine.	Diltiazem	189-198	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	164-170	
20514078-0	2011	Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.	Diltiazem	11-20	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	70-76	
20514078-2	2011	In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively).	Diltiazem	49-58	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	154-160	
20514078-2	2011	In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively).	Diltiazem	49-58	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	180-186	
20514078-4	2011	For CYP3A5 expressers, an algorithm guided by CYP3A5 and diltiazem significantly reduced tacrolimus maintenance dosage (P=0.009) and improved the accuracy of tacrolimus initial dose, resulting in reduction in out-of-range C(0) after initial dose (P=0.002) and dose adjustments (P=0.004).	Diltiazem	57-66	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	4-10	
20514078-6	2011	Our study results show that CYP3A5 genotype-guided tacrolimus-diltiazem combination is a promising therapy in renal transplant recipients in the early postoperative stage.	Diltiazem	62-71	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	28-34	
21356216-3	2011	MAIN METHODS: Diltiazem N-demethylase activity of recombinant CYP3A4, CYP3A5, CYP3A7, and human liver microsomes (HLMs) in the presence of cannabinoids was determined.	Diltiazem	14-23	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	70-76	
18589174-6	2008	Among 18 TAC-treated recipients, all receiving Diltiazem (DTZ), the median C/D ratio was lower for CYP3A5 *1/*1 versus *1/*3 versus *3/*3 (1.9, 4.6, and 13.5 ng/mL per 0.1 mg/kg/d, respectively; P = .001).	Diltiazem	47-56	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105	
18589174-6	2008	Among 18 TAC-treated recipients, all receiving Diltiazem (DTZ), the median C/D ratio was lower for CYP3A5 *1/*1 versus *1/*3 versus *3/*3 (1.9, 4.6, and 13.5 ng/mL per 0.1 mg/kg/d, respectively; P = .001).	Diltiazem	58-61	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105	
16024008-0	2005	Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem.	Diltiazem	70-79	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	15-21	
16024008-8	2005	CONCLUSION: The results suggest that CYP3A5*3 has only a minor effect on the pharmacokinetics and metabolism of diltiazem.	Diltiazem	112-121	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	37-43	
15377640-11	2004	In conclusion, erythromycin, diltiazem, and nicardipine were weaker inhibitors of CYP3A5 and inactivated the enzyme at a slower rate than their respective effects on CYP3A4.	Diltiazem	29-38	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	82-88	
15499178-6	2004	In addition, the correlation coefficients of CYP3A5 contents with the rates of diltiazem N-demethylation, midazolam 1"-hydroxylation and testosterone 6beta- hydroxylation were higher than those of CYP3A4, although the value of CYP3A5 with the midazolam 4-hydroxylation rate was similar to that of CYP3A4.	Diltiazem	79-88	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	45-51	
15499178-8	2004	The apparent V(max)/K(m) values for recombinant CYP3A5 indicated the greater contributions to diltiazem N-demethylation and midazolam 1"-hydroxylation as compared with CYP3A4.	Diltiazem	94-103	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	48-54	
15499178-9	2004	These results suggest that polymorphic CYP3A5 contributes markedly to the drug oxidations, particularly diltiazem N-demethylation, midazolam 1"- hydroxylation and testosterone 6beta-hydroxylation by liver microsomes from Japanese subjects.	Diltiazem	104-113	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	39-45